Clinical trial
STI571 ProspectIve RandomIzed Trial: SPIRIT
NCT00219739 · Poitiers University Hospital, Other · Completed
Key facts
| NCT number | NCT00219739 |
|---|---|
| Title | STI571 ProspectIve RandomIzed Trial: SPIRIT |
| Official title | A Phase III Prospective Randomized Comparison of Imatinib at a Dose of 400mg in Combination With Peg-Interferon-alpha2a (Peg-IFNa2a) or Cytarabine (Ara-C)Versus Imatinib at a Dose of 600mg Versus Imatinib a Dose of 400mg for Previously Untreated Chronic Myelogenous Leukemia (CML) in Chronic Phase |
| Acronym | SPIRIT |
| Lead sponsor | Poitiers University Hospital, Other |
| Collaborators | Ministry of Health, France Novartis Industry Roche Pharma AG |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Imatinib mesylate 400 mg, Imatinib mesylate 600 mg, Imatinib 400 mg + Peg-Interferon, Imatinib mesylate 400 mg + Cytarabine |
| Enrollment | 789 |
| Start date | Sep 1, 2003 |
| Primary completion | Dec 1, 2014 |
| Completion | Dec 1, 2014 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 13, 2020 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: